3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
4
Oligodendroglioma
2
Astrocytoma
2
Recurrence
1
Pathologic Processes
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Healthy Adult Participants
1
Disease Attributes
1
Interventions
Oncolytic Virotherapy
2
vorasidenib
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
Vorinostat
1
Radiation
1
ONC206
1
Interferon-gamma
1
Immunotherapy
1
Antibodies, Monoclonal
1
Afatinib
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroectodermal Tumors
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing